Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 2 Withdrawn 1 Unknown 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroendocrine Tumors 19 Carcinoid Tumor 7 Pheochromocytoma 6 Thyroid Carcinoma, Anaplastic 5 Pituitary Neoplasms 5 Paraganglioma 5 Insulinoma 5 Somatostatinoma 4 Vipoma 3 Serotonin Syndrome 3 Lung Neoplasms 3 Glucagonoma 3 Gastro-enteropancreatic neuroendocrine tumor 3 Gastrinoma 3 Carcinoma, Neuroendocrine 3 Carcinoma, Merkel Cell 3 Carcinoma, Medullary 3 Carcinoma, Islet Cell 3 Thyroid Neoplasms 2 Small Cell Lung Carcinoma 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Neuroblastoma 2 Neoplasms, Unknown Primary 2 Neoplasms 2 Multiple Endocrine Neoplasia Type 1 2 Head and Neck Neoplasms 2 Growth Hormone-Secreting Pituitary Adenoma 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2

Interventions

telotristat ethyl 1 lanreotide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Carcinoid Heart Disease × Endocrine × Clear all

NCT04065165 2020-02-05

TELEFIRST

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Withdrawn

Carcinoid Heart Disease, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡